Skip to content

The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging

Mahul B. Amin, Frederick L. Greene, Stephen B. Edge, Carolyn C. Compton, Robert K. Brookland, Donna M. Gress, David R. Byrd, David Porter Winchester

CA A Cancer Journal for Clinicians · 2017 · 6,930 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017). The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA A Cancer Journal for Clinicians, 67(2), 93–99. https://doi.org/10.3322/caac.21388

In text: (Amin et al., 2017)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining the best treatment approaches. Many view the primary role of the tumor, lymph node, metastasis (TNM) system as that of a standardized classification system for evaluating cancer at a population level in terms of the extent of disease, both at initial presentation and after surgical treatment, and the overall impact of improvements in cancer treatment. The rapid evolution of knowledge in cancer biology and the discovery and validation of biologic factors that predict cancer outcome and response to treatment with better accuracy have led some cancer experts to question the utility of a TNM-based approach in clinical care at an individualized patient level. In the Eighth Edition of the AJCC Cancer Staging Manual, the goal of including relevant, nonanatomic (including molecular) factors has been foremost, although changes are made only when there is strong evidence for inclusion. The editorial board viewed this iteration as a proactive effort to continue to build the important bridge from a "population-based" to a more "personalized" approach to patient classification, one that forms the conceptual framework and foundation of cancer staging in the era of precision molecular oncology. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge-based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as "what's new" in the Eighth Edition. It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. CA Cancer J Clin 2017;67:93-99. © 2017 American Cancer Society.

  1. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer2016
  2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene1987
  3. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer1989
  4. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer2005
  5. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer2005

Metadata from OpenAlex (CC0). Citations are generated from the published record.